Armata Pharmaceuticals, Inc. 8-K
Leadership change
Pfizer commercial quality executive Daniel B. Gilmer joins the board; he previously led the U.S. launch of PAXLOVID.
Filed 2026-04-27 07:10 ET
- 5.02 Officer/director change
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Board appointment. Armata appointed Daniel B. Gilmer, Ph.D., effective 4/24/2026, to serve until the next annual shareholder meeting. Gilmer is a Pfizer commercial quality executive and previously led the U.S. launch of PAXLOVID.
Key Figures
- Director compensation: $0.04M annual cash retainer; expected option grant for 51,280 shares at fair market value on the grant date, vesting in equal installments over three years. Other equity awards are subject to Board determination.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3